PMID- 9529127
OWN - NLM
STAT- MEDLINE
DCOM- 19980416
LR  - 20190914
IS  - 0887-6924 (Print)
IS  - 0887-6924 (Linking)
VI  - 12
IP  - 3
DP  - 1998 Mar
TI  - Quality of IL-3 and G-CSF-mobilized peripheral blood stem cells in patients with 
      early chronic phase CML.
PG  - 333-9
AB  - Coexistence of Philadelphia chromosome (Ph)-negative, primitive hematopoietic 
      progenitor cells with their malignant counterparts in chronic myelogenous 
      leukemia (CML) has been reported. As most of the Ph-negative progenitor cells do 
      not express the HLA-DR antigen, selection of them might be possible. Peripheral 
      blood progenitor cells (PBPC) from eight early chronic phase (CML) patients were 
      mobilized by ICE chemotherapy followed by simultaneous administration of 
      recombinant human granulocyte colony-stimulating factor (rhG-CSF) and recombinant 
      human interleukin 3 (rhIL-3). PBPCs were collected by leukapheresis in the early 
      phase of hematopoietic recovery after chemotherapy, CD34 selected and cultured in 
      vitro. The content of Ph chromosome-positive cells in leukapheresis products as 
      well as after CD34 enrichment and after in vitro culture was analyzed by 
      interphase fluorescence in situ hybridization (FISH) and RT-PCR. The percentage 
      of Ph chromosome-positive PBPC was reduced after each purification step in almost 
      all samples. A substantial number of PBPC samples were negative for the bcr/abl 
      mRNA rearrangement as analyzed by RT-PCR. The present study demonstrates the 
      feasibility of mobilizing Ph-negative PBPC during the early phase of 
      hematopoietic recovery after ICE chemotherapy and simultaneous administration of 
      rhIL-3 and rhG-CSF.
FAU - Heinzinger, M
AU  - Heinzinger M
AD  - Department of Hematology/Oncology, University Medical Center Freiburg, Germany.
FAU - Waller, C F
AU  - Waller CF
FAU - Rosenstiel, A
AU  - Rosenstiel A
FAU - Scheid, S
AU  - Scheid S
FAU - Burger, K J
AU  - Burger KJ
FAU - Lange, W
AU  - Lange W
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Leukemia
JT  - Leukemia
JID - 8704895
RN  - 0 (Antigens, CD34)
RN  - 0 (Interferon-alpha)
RN  - 0 (Interleukin-3)
RN  - 0 (Recombinant Proteins)
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
RN  - 6PLQ3CP4P3 (Etoposide)
RN  - EC 2.7.10.2 (Fusion Proteins, bcr-abl)
RN  - Q20Q21Q62J (Cisplatin)
RN  - UM20QQM95Y (Ifosfamide)
RN  - ICE protocol 1
SB  - IM
MH  - Adult
MH  - Antigens, CD34/blood
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Bone Marrow/pathology
MH  - Cells, Cultured
MH  - Cisplatin/administration & dosage
MH  - Combined Modality Therapy
MH  - Etoposide/administration & dosage
MH  - Female
MH  - Fusion Proteins, bcr-abl/genetics
MH  - Gene Rearrangement
MH  - Granulocyte Colony-Stimulating Factor/*therapeutic use
MH  - Hematopoiesis/*drug effects
MH  - Hematopoietic Stem Cells/*drug effects/pathology
MH  - Humans
MH  - Ifosfamide/administration & dosage
MH  - Immunophenotyping
MH  - Interferon-alpha/therapeutic use
MH  - Interleukin-3/*therapeutic use
MH  - Leukapheresis
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug 
      therapy/genetics/pathology/*therapy
MH  - Male
MH  - Middle Aged
MH  - Philadelphia Chromosome
MH  - Polymerase Chain Reaction
MH  - Recombinant Proteins/therapeutic use
EDAT- 1998/04/07 00:00
MHDA- 1998/04/07 00:01
CRDT- 1998/04/07 00:00
PHST- 1998/04/07 00:00 [pubmed]
PHST- 1998/04/07 00:01 [medline]
PHST- 1998/04/07 00:00 [entrez]
AID - 10.1038/sj.leu.2400960 [doi]
PST - ppublish
SO  - Leukemia. 1998 Mar;12(3):333-9. doi: 10.1038/sj.leu.2400960.